Zoetis Inc. $ZTS Position Increased by Avanza Fonder AB

Key Points

• Avanza Fonder AB increased its stake in Zoetis Inc. by 7.8% in the second quarter, now holding over 45,000 shares valued at approximately $7 million.
• Zoetis reported a net margin of 27.83% and a year-over-year revenue increase of 4.2%, with earnings per share of $1.76, surpassing analyst estimates.
• Current consensus rating for Zoetis stock is "Moderate Buy" with a target price averaging $200.88 among several analysts, reflecting mixed outlooks with some downgrades recently.

Avanza Fonder AB raised its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 7.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,121 shares of the company's stock after acquiring an additional 3,246 shares during the period. Avanza Fonder AB's holdings in Zoetis were worth $7,037,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. purchased a new stake in Zoetis during the first quarter worth approximately $25,000. 1248 Management LLC acquired a new position in shares of Zoetis during the 1st quarter valued at $27,000. Saudi Central Bank acquired a new position in shares of Zoetis during the 1st quarter valued at $29,000. Cornerstone Planning Group LLC boosted its position in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. increased its holdings in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ZTS shares. Argus restated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Stock Down 0.8%

Shares of ZTS traded down $1.15 during trading on Monday, reaching $144.73. The company's stock had a trading volume of 2,044,648 shares, compared to its average volume of 3,032,367. The company has a fifty day moving average of $151.25 and a two-hundred day moving average of $156.45. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $197.51. The company has a market cap of $64.14 billion, a price-to-earnings ratio of 24.91, a P/E/G ratio of 2.34 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the company posted $1.56 EPS. Zoetis's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.